Biosimilar Naming: How Do Adverse Event Reporting Data Support the Need for Distinct Nonproprietary Names for Biosimilars?

FDLI FOOD AND DRUG POLICY FORUM vol.3:no.6 (2013)

Faculty

Erika Lietzan

Databases